je.st
news
Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Clinical Trial Data
2015-04-01 07:37:14| drugdiscoveryonline Home Page
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases recently announced that data from the Company’s Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting
Tags: data
life
present
cell
Category:Biotechnology and Pharmaceuticals